Heidi E. Greulich
Impact in
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 26
-
- Cancer Genomics and Diagnostics 11
- Co-authors
- Matthew Meyerson (25 shared papers)Michael J. Eck (5 shared papers)William R. Sellers (8 shared papers)Titus J. Boggon (2 shared papers)Pasi Antero Janne (4 shared papers)Bruce Evan Johnson (2 shared papers)Jeffrey C. Lee (2 shared papers)Katsuhiko Naoki (1 shared paper)
- Journals
- Cancer Research (9 papers)Nature (7 papers)Proceedings of the National Academy of Sciences (5 papers)Journal of Biological Chemistry (4 papers)Cell (3 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Heidi E. Greulich
70 papers receiving 30.2k citations
Heidi E. Greulich's Hit Papers
Peers
Comparison fields: 5 of 158
- Cancer Research 6.8k
- Oncology 11.1k
- Pulmonary and Respiratory Medicine 12.4k
- Molecular Biology 15.6k
- Genetics 1.6k
Countries citing papers authored by Heidi E. Greulich
This map shows the geographic impact of Heidi E. Greulich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi E. Greulich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi E. Greulich more than expected).
Fields of papers citing papers by Heidi E. Greulich
This network shows the impact of papers produced by Heidi E. Greulich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi E. Greulich. The network helps show where Heidi E. Greulich may publish in the future.
Co-authors
The 25 scholars most cited alongside Heidi E. Greulich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 72 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy Hit paper breakdown → | 2004 | 8145 |
| 2 | The landscape of somatic copy-number alteration across human cancers Hit paper breakdown → | 2010 | 3151 |
| 3 | Somatic mutations affect key pathways in lung adenocarcinoma Hit paper breakdown → | 2008 | 2237 |
| 4 | The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Hit paper breakdown → | 2008 | 1737 |
| 5 | Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing Hit paper breakdown → | 2012 | 1516 |
| 6 | BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Hit paper breakdown → | 2008 | 1270 |
| 7 | Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Hit paper breakdown → | 2007 | 983 |
| 8 | Characterizing the cancer genome in lung adenocarcinoma Hit paper breakdown → | 2007 | 924 |
| 9 | High-throughput oncogene mutation profiling in human cancer Hit paper breakdown → | 2007 | 862 |
| 10 | Landscape of genomic alterations in cervical carcinomas Hit paper breakdown → | 2013 | 728 |
| 11 | Activating mutations in ALK provide a therapeutic target in neuroblastoma Hit paper breakdown → | 2008 | 717 |
| 12 | Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations Hit paper breakdown → | 2012 | 631 |
| 13 | Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Hit paper breakdown → | 2010 | 610 |
| 14 | Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants Hit paper breakdown → | 2005 | 587 |
| 15 | Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome Hit paper breakdown → | 2010 | 579 |
| 16 | Discovering the anticancer potential of non-oncology drugs by systematic viability profiling Hit paper breakdown → | 2020 | 575 |
| 17 | 2007 | 499 | |
| 18 | Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer Hit paper breakdown → | 2011 | 400 |
| 19 | 2011 | 322 | |
| 20 | 2008 | 311 |
About Heidi E. Greulich
Heidi E. Greulich is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Molecular Biology and Genetics, having authored 72 papers that have together received 31.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (26 papers), HER2/EGFR in Cancer Research (13 papers), Cancer Genomics and Diagnostics (11 papers), Cancer therapeutics and mechanisms (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Phosphodiesterase function and regulation (6 papers), RNA modifications and cancer (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). The work is most often cited by research in Cancer Research (6.8k citations), Oncology (11.1k citations), Pulmonary and Respiratory Medicine (12.4k citations), Molecular Biology (15.6k citations) and Genetics (1.6k citations). Heidi E. Greulich has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Matthew Meyerson, Michael J. Eck, William R. Sellers, Titus J. Boggon, Pasi Antero Janne, Bruce Evan Johnson, Jeffrey C. Lee, Katsuhiko Naoki, Yoshitaka Fujii and Sean I. Tracy. Their work appears in journals such as Cancer Research, Nature, Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.